LungLife AI, INC Result of Special Meeting

RNS Number : 8390H

LungLife AI, INC

21 March 2024

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

 

21 March 2024

LungLife AI, Inc.

 

(the "Company" or "LungLife")

 

Result of Special Meeting

 

LungLife AI, Inc. (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that at the Special Meeting held earlier today, all resolutions proposed were duly passed by shareholders. A summary of the voting results is shown below:

 

	For	Against	Withheld	Total Votes Cast	% Voting For*
Resolution 1	19,992,507	20,006	0	20,012,513	78.45%
Resolution 2	19,992,507	20,006	0	20,012,513	78.45%
Resolution 3	19,992,507	20,006	0	20,012,513	78.45%
Resolution 4	19,992,507	20,006	0	20,012,513	78.45%

* This column represents the number of votes that were cast for the resolutions as a percentage of the total issued and outstanding shares of the Company as at the record date for the meeting.

Accordingly, subject to admission of the New Shares to trading on AIM, the Company has raised a total of £1.8 million (before expenses) via the Placing and Subscription through the issue and allotment of 5,172,621 new Common Shares. An application has been made for the New Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 22 March 2024.

Unless otherwise defined in this announcement, capitalised terms used in this announcement shall have the same meanings as defined in the Company's announcement of 4 March 2024.

 

Enquiries:

 

 

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Joint Broker)	Tel: [phone]
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody Stockbrokers UC (Joint Broker) Tom Nicholson / Cameron Duncan / William Hall	Tel: [phone]
Walbrook PR Limited	Tel: [phone]
Paul McManus / Alice Woodings / Phillip Marriage	or [e-mail]

 

 

About LungLife AI Inc

 

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com.

 

 

IMPORTANT NOTICES

THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN THEM, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION, FORWARDING OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any State or other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in or into the United States, or to or for the account or benefit of US persons (as defined in Regulation S under the Securities Act ("Regulation S")), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any State or any other jurisdiction of the United States.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

ROMUARSRSSUOUAR